Innovative solutions for visualizing in vivo biology
Our proprietary technologies provide unprecedented insights into tumor biology and drug action.
Illuminate Cancer Research with Precision
FluoroCell™ is a proprietary technology platform dedicated to generating fluorescently labeled cancer cell lines for advanced preclinical research. Designed for real-time in vivo imaging, FluoroCell™ enables accurate tracking of tumor growth, metastasis, and treatment response. This platform enhances data richness in oncology studies by providing high-resolution visualization and facilitating quantitative bioinformatics analysis. FluoroCell™ empowers researchers with powerful tools to accelerate drug discovery, tumor biology insights, and translational medicine.
Illuminate Tumors with Precision
OncoReveal™ is an innovative tumor-tracing platform powered by proprietary carbon quantum dots (CQDs) that selectively accumulate in patient-derived xenograft (PDX) tumors without altering their growth. This cutting-edge technology delivers highly sensitive, non-toxic, and non-invasive imaging, enabling real-time visualization of tumor progression and metastasis. With broad tumor applicability and exceptional biocompatibility, OncoReveal™ empowers researchers and clinicians with a reliable tool for preclinical oncology studies and personalized therapeutic development.
Unlocking the Power of Tumor Exosomes
Tumor-derived exosomes are transforming our understanding of cancer biology — from reshaping the tumor microenvironment to mediating long-range communication and enabling smarter therapeutic interventions.
OncoExo™ stands at the forefront of this revolution, offering researchers and innovators access to high-purity, high-quality tumor exosomes that meet the rigorous demands of next-generation biomedical research.
With OncoExo™, you gain more than just a product — you gain a partner in precision oncology, committed to accelerating discovery, enhancing data reliability, and empowering the future of personalized medicine.
Our platform utilizes the advanced EchoMRI™ system to provide precise, non-invasive body composition analysis in small animal models of obesity, diabetes, and metabolic syndrome. With rapid and repeatable measurements of fat mass, lean mass, and body water, the platform enables dynamic monitoring of disease progression and therapeutic effects.
It supports a wide range of metabolic research applications including drug efficacy testing, genetic model phenotyping, and nutritional studies.
Fully compatible with metabolic cages, GTT/ITT, and imaging technologies, this platform offers a powerful foundation for integrated metabolic disease research and drug development.
Contact our scientific team for a detailed discussion.